Committed to helping Fight Disease
Reata’s lead candidates, omaveloxolone and bardoxolone methyl, are being developed for the treatment of a variety of chronic and genetic diseases for which a substantial unmet need exists. Our pipeline of therapeutics is focused in two main pillars: neurology and chronic kidney disease (CKD), with late stage programs in Friedreich's ataxia, Alport syndrome, and autosomal dominant polycystic kidney disease (ADPKD).